Do analysts prefer ITRM or GELS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, ITRM or GELS?

Gelteq has lower revenue, but higher earnings than Iterum Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Iterum Therapeutics $390K 4.10 -$24.77M -$0.75 N/A Gelteq $110K 60.46 -$4.30M N/A N/A

Is ITRM or GELS more profitable?

Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% Gelteq N/A N/A N/A

Do analysts rate ITRM or SNOA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend ITRM or NCNA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ITRM or NCNA more profitable?

Iterum Therapeutics' return on equity of 0.00% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% NuCana N/A -153.61% -116.03%

Is RVPH or ITRM more profitable?

Iterum Therapeutics' return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Reviva Pharmaceuticals N/A -391.58% -119.08% Iterum Therapeutics N/A N/A -65.54%

Do analysts prefer ITRM or PULM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Pulmatrix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ITRM or PULM more profitable?

Iterum Therapeutics' return on equity of 0.00% beat Pulmatrix's return on equity. Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% Pulmatrix N/A -107.84% -91.58%

Iterum Therapeutics (ITRM) Competitors

$0.03 0.00 (0.00%)

As of 08/13/2026

Compare

ITRM vs. GELS, SNOA, NCNA, RVPH, and PULM

Should you buy Iterum Therapeutics stock or one of its competitors? Iterum Therapeutics's main competitors and comparable companies include Gelteq (GELS), Sonoma Pharmaceuticals (SNOA), NuCana (NCNA), Reviva Pharmaceuticals (RVPH), and Pulmatrix (PULM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Iterum Therapeutics compare to Gelteq?

Iterum Therapeutics (NASDAQ:ITRM) and Gelteq (NASDAQ:GELS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, Gelteq had 1 more articles in the media than Iterum Therapeutics. MarketBeat recorded 1 mentions for Gelteq and 0 mentions for Iterum Therapeutics. Gelteq's average media sentiment score of 1.87 beat Iterum Therapeutics' score of 0.00 indicating that Gelteq is being referred to more favorably in the news media.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
Gelteq	Very Positive

Iterum Therapeutics has a beta of 2.96, suggesting that its stock price is 196% more volatile than the broader market. Comparatively, Gelteq has a beta of -0.45, suggesting that its stock price is 145% less volatile than the broader market.

9.2% of Iterum Therapeutics shares are held by institutional investors. 2.0% of Iterum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Gelteq has lower revenue, but higher earnings than Iterum Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
Gelteq	$110K	60.46	-$4.30M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Gelteq	N/A	N/A	N/A

Summary

Iterum Therapeutics and Gelteq tied by winning 5 of the 10 factors compared between the two stocks.

How does Iterum Therapeutics compare to Sonoma Pharmaceuticals?

Iterum Therapeutics (NASDAQ:ITRM) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Iterum Therapeutics has a beta of 2.96, meaning that its share price is 196% more volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market.

Iterum Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -10.33%. Iterum Therapeutics' return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Sonoma Pharmaceuticals	-10.33%	-26.32%	-6.55%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Sonoma Pharmaceuticals had 2 more articles in the media than Iterum Therapeutics. MarketBeat recorded 2 mentions for Sonoma Pharmaceuticals and 0 mentions for Iterum Therapeutics. Sonoma Pharmaceuticals' average media sentiment score of 1.44 beat Iterum Therapeutics' score of 0.00 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
Sonoma Pharmaceuticals	Positive

Sonoma Pharmaceuticals has higher revenue and earnings than Iterum Therapeutics. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
Sonoma Pharmaceuticals	$21.92M	0.29	-$3.17M	-$1.22	N/A

9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Iterum Therapeutics beats Sonoma Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Iterum Therapeutics compare to NuCana?

Iterum Therapeutics (NASDAQ:ITRM) and NuCana (NASDAQ:NCNA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

Iterum Therapeutics has a beta of 2.96, suggesting that its share price is 196% more volatile than the broader market. Comparatively, NuCana has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market.

In the previous week, NuCana had 3 more articles in the media than Iterum Therapeutics. MarketBeat recorded 3 mentions for NuCana and 0 mentions for Iterum Therapeutics. NuCana's average media sentiment score of 1.63 beat Iterum Therapeutics' score of 0.00 indicating that NuCana is being referred to more favorably in the news media.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
NuCana	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Iterum Therapeutics has higher revenue and earnings than NuCana. NuCana is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A

Iterum Therapeutics' return on equity of 0.00% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
NuCana	N/A	-153.61%	-116.03%

9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 44.0% of NuCana shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 31.2% of NuCana shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Iterum Therapeutics beats NuCana on 8 of the 12 factors compared between the two stocks.

How does Iterum Therapeutics compare to Reviva Pharmaceuticals?

Reviva Pharmaceuticals (NASDAQ:RVPH) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, Reviva Pharmaceuticals had 4 more articles in the media than Iterum Therapeutics. MarketBeat recorded 4 mentions for Reviva Pharmaceuticals and 0 mentions for Iterum Therapeutics. Reviva Pharmaceuticals' average media sentiment score of 0.50 beat Iterum Therapeutics' score of 0.00 indicating that Reviva Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Reviva Pharmaceuticals	Neutral
Iterum Therapeutics	Neutral

Iterum Therapeutics' return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%
Iterum Therapeutics	N/A	N/A	-65.54%

63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 8.9% of Reviva Pharmaceuticals shares are owned by company insiders. Comparatively, 2.0% of Iterum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Reviva Pharmaceuticals has higher earnings, but lower revenue than Iterum Therapeutics. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A

Reviva Pharmaceuticals has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Iterum Therapeutics has a beta of 2.96, suggesting that its stock price is 196% more volatile than the broader market.

Reviva Pharmaceuticals presently has a consensus price target of $66.67, indicating a potential upside of 14,236.92%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Reviva Pharmaceuticals is more favorable than Iterum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Reviva Pharmaceuticals beats Iterum Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Iterum Therapeutics compare to Pulmatrix?

Iterum Therapeutics (NASDAQ:ITRM) and Pulmatrix (NASDAQ:PULM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Iterum Therapeutics' return on equity of 0.00% beat Pulmatrix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Pulmatrix	N/A	-107.84%	-91.58%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Pulmatrix had 5 more articles in the media than Iterum Therapeutics. MarketBeat recorded 5 mentions for Pulmatrix and 0 mentions for Iterum Therapeutics. Pulmatrix's average media sentiment score of 1.34 beat Iterum Therapeutics' score of 0.00 indicating that Pulmatrix is being referred to more favorably in the news media.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
Pulmatrix	Positive

Pulmatrix has higher revenue and earnings than Iterum Therapeutics. Pulmatrix is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
Pulmatrix	$7.81M	0.74	-$5.16M	-$1.23	N/A

9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 11.8% of Pulmatrix shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 0.6% of Pulmatrix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Iterum Therapeutics has a beta of 2.96, meaning that its stock price is 196% more volatile than the broader market. Comparatively, Pulmatrix has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market.

Summary

Iterum Therapeutics beats Pulmatrix on 8 of the 13 factors compared between the two stocks.

Get Iterum Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ITRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ITRM vs. The Competition

Export

Metric	Iterum Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.60M	$11.70B	$6.97B	$13.06B
Dividend Yield	N/A	2.70%	2.58%	10.72%
P/E Ratio	-0.04	783.85	269.56	25.27
Price / Sales	4.10	747.98	596.64	100.41
Price / Cash	N/A	67.45	70.53	50.75
Price / Book	-0.20	10.66	13.00	6.30
Net Income	-$24.77M	$2.77B	$3.45B	$347.83M
7 Day Performance	N/A	-0.25%	0.57%	0.94%
1 Month Performance	N/A	-0.10%	1.22%	0.90%
1 Year Performance	N/A	160.98%	66.67%	20.40%

Iterum Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ITRM Iterum Therapeutics	0.0318 of 5 stars	$0.03 flat	N/A	N/A	$1.60M	$390K	N/A	10
GELS Gelteq	1.2892 of 5 stars	$0.57 -2.4%	N/A	-59.1%	$6.26M	$110K	N/A	N/A
SNOA Sonoma Pharmaceuticals	1.0908 of 5 stars	$1.37 +6.2%	N/A	-56.2%	$6.18M	$19.53M	N/A	180	Positive News Short Interest Decrease
NCNA NuCana	1.0814 of 5 stars	$1.44 flat	N/A	-67.5%	$5.99M	N/A	N/A	30	News Coverage Earnings Report
RVPH Reviva Pharmaceuticals	2.5208 of 5 stars	$0.45 +4.7%	$66.67 +14,714.8%	-94.5%	$5.90M	N/A	N/A	5	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ITRM) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Iterum Therapeutics (ITRM) Competitors

ITRM vs. GELS, SNOA, NCNA, RVPH, and PULM

How does Iterum Therapeutics compare to Gelteq?

Summary

How does Iterum Therapeutics compare to Sonoma Pharmaceuticals?

Summary

How does Iterum Therapeutics compare to NuCana?

Summary

How does Iterum Therapeutics compare to Reviva Pharmaceuticals?

Summary

How does Iterum Therapeutics compare to Pulmatrix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITRM vs. The Competition

Iterum Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Iterum Therapeutics (ITRM) Competitors

ITRM vs. GELS, SNOA, NCNA, RVPH, and PULM

How does Iterum Therapeutics compare to Gelteq?

Does the media refer more to ITRM or GELS?

Which has more volatility and risk, ITRM or GELS?

Do insiders and institutionals believe in ITRM or GELS?

Do analysts prefer ITRM or GELS?

Which has stronger valuation and earnings, ITRM or GELS?

Is ITRM or GELS more profitable?

Summary

How does Iterum Therapeutics compare to Sonoma Pharmaceuticals?

Which has more risk and volatility, ITRM or SNOA?

Is ITRM or SNOA more profitable?

Do analysts rate ITRM or SNOA?

Does the media prefer ITRM or SNOA?

Which has better earnings & valuation, ITRM or SNOA?

Do insiders and institutionals have more ownership in ITRM or SNOA?

Summary

How does Iterum Therapeutics compare to NuCana?

Which has more risk and volatility, ITRM or NCNA?

Does the media prefer ITRM or NCNA?

Do analysts recommend ITRM or NCNA?

Which has higher earnings and valuation, ITRM or NCNA?

Is ITRM or NCNA more profitable?

Do institutionals & insiders believe in ITRM or NCNA?

Summary

How does Iterum Therapeutics compare to Reviva Pharmaceuticals?

Does the media refer more to RVPH or ITRM?

Is RVPH or ITRM more profitable?

Do insiders & institutionals hold more shares of RVPH or ITRM?

Which has preferable earnings & valuation, RVPH or ITRM?

Which has more risk and volatility, RVPH or ITRM?

Do analysts prefer RVPH or ITRM?

Summary

How does Iterum Therapeutics compare to Pulmatrix?

Is ITRM or PULM more profitable?

Do analysts prefer ITRM or PULM?

Does the media refer more to ITRM or PULM?

Which has stronger valuation & earnings, ITRM or PULM?

Do institutionals & insiders hold more shares of ITRM or PULM?

Which has more risk and volatility, ITRM or PULM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITRM vs. The Competition

Iterum Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools